Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Cash & Equivalents (2016 - 2025)

Sonoma Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $2.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 51.09% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, down 51.09%, while the annual FY2025 figure was $5.4 million, 71.8% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $2.6 million at Sonoma Pharmaceuticals, down from $3.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $8.5 million in Q4 2021 and troughed at $2.1 million in Q3 2023.
  • A 5-year average of $4.2 million and a median of $3.6 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: tumbled 69.12% in 2022 and later surged 117.62% in 2024.
  • Year by year, Cash & Equivalents stood at $8.5 million in 2021, then tumbled by 69.12% to $2.6 million in 2022, then fell by 8.66% to $2.4 million in 2023, then surged by 117.62% to $5.2 million in 2024, then crashed by 51.09% to $2.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for SNOA at $2.6 million in Q4 2025, $3.0 million in Q3 2025, and $3.6 million in Q2 2025.